Notable Labs is a personalized testing service for cancer patients that prioritizes combinations of FDA-approved treatments that can be immediately prescribed by a doctor without a clinical trial.
Foresight is a technology-enabled psychiatry and therapy services company. We directly employ psychiatrists, therapists, psychiatric nurse practitioners to treat patients in our offices. Our team of software and biomedical engineers create technology alongside our providers to revolutionize the care we provide.
Octant Bio is a developer of synthetic technology used to improve health and treat disease. Its technology uses synthetic biology, genome engineering, next-generation sequencing, and computational tools to simultaneously measure the activity of thousands of receptor pathways in human cells that enable scientists to apply machine learning methods to engineer small molecules that interact with multiple receptors and unlock a new potential to treat complex diseases.
Alto Neuroscience is a clinical-stage biopharmaceutical company that integrates the biology of the patient into drug development to improve the lives of people with mental health conditions. Through its AI-enabled biomarker platform, Alto Neuroscience combines rich sources of information on patients’ brain activity and behavior to rapidly develop highly-effective medicines for targeted populations. Alto Neuroscience aims to replace today's trial-and-error clinical approach by aligning the right Alto drug with the right patient, redefining psychiatry at a time when the world needs it most.
Bionaut Labs revolutionizes the treatment of central nervous system disorders with its precision medicine treatment modality. By creating a new medical modality of remote-controlled micro-robots called Bionauts, the company can transform the way the biopharmaceutical industry develops treatments, allowing them to engineer the therapeutic index for efficacy and maintain safety. Bionaut Labs is focused on helping patients suffering from debilitating brain diseases who have few available treatment options. The anatomical targeting capabilities of the Bionaut platform make new therapeutics technologies such as gene therapy, CRISPR-Cas9, and oncolytic viruses viable in challenging clinical settings.
Eigen Therapeutics is a biotechnology company on a mission to make therapies that make cancer easier to find and eliminate. Eigen is focused on the development of “priming” therapies, therapies that help targeted therapies reach their full potential by addressing cancer heterogeneity, making cancer cells more vulnerable and/or making healthy cells more resilient to treatment. Eigen is building a high-throughput discovery platform to explore the space of priming therapies, leveraging proprietary machine learning algorithms to discover novel associations, new classes of drugs, and new potential therapies that change a cell's state to make it more vulnerable to a targeted therapy. The Eigen platform represents the intersection of biology and engineering, and includes robotic systems, laboratory operations software, and machine learning analysis pipelines—all developed in-house—with the ultimate goal of saving more lives.
Circularis Biotechnologies develops a revolutionary technology to regulate gene expression and enable increased biotherapeutic production. It was founded in 2014 and is headquartered in Oakland, California.
Ochre Bio develops genomic medicines to rejuvenate donors' livers before transplant, so that everyone who needs a new liver gets one. They use genomics to find and shut down over-active genes driving disease and then go directly to testing therapies in discarded donor livers that keep alive outside of the body. Ochre Bio is within the heart of Oxford’s biotech innovation hub. Their scientific roots can be traced back to over 15 years leading liver genomics research and experience in bringing advanced therapies to market.
NutriSense is a health and wellness platform that monitors blood glucose levels in real-time with CGM and a tracking app. It personalizes nutrition by leveraging state-of-the-art continuous glucose monitoring and machine learning technology. The company's mission is to help anybody discover and reach their health potential. NutriSense was founded in 2019 and is based in Chicago, Illinois.
BioROSA Technologies creates a biologically-based diagnostic standard of care for Autism Spectrum Disorders. The company was founded in 2018 and is based in Belmont, Massachusetts.
Juno Diagnostics is a health technology company democratizing access to high-value genetic information. The company is developing simple, cost-effective devices that enable point-of-need genetic testing. It was founded in 2017 and is based in San Diego, California.
HepaTx is developing regenerative medicine solutions to address the need for better therapies for life-threatening liver diseases. The technology invented at Stanford University enables efficient hepatocyte production for therapeutic purposes. Its therapeutics can replace lost liver function to treat those with end-stage of liver disease, potentially saving the cost and morbidity of whole organ transplant.
Juno Diagnostics is a health technology company democratizing access to high-value genetic information. The company is developing simple, cost-effective devices that enable point-of-need genetic testing. It was founded in 2017 and is based in San Diego, California.
Based in the Boston biotech and medtech hub, Elucid is focused on improving the accuracy, experience, & cost-effectiveness of cardiovascular diagnostic imaging by leveraging machine learning. Elucid's main product, ElucidVivo, is the first-ever, FDA-cleared, histologically-validated software for evaluating plaque vulnerability from a single CTA to inform risk of event (heart attack or stroke) & treatment selection. Additionally, Elucid works with pharmaceutical companies, providers, and research organizations to provide quantitative image analysis services.
IVIVA Medical was founded with the goal of developing autologous tissue constructs as a solution to end-state renal disease (ESRD). End-stage renal disease affects over 500,000 patients in the United States and despite transplant being the only definitive treatment for ESRD, most will never receive a donor kidney. Our team is leveraging emerging complementary technologies in tissue engineering, 3D additive manufacturing, and stem cell biology in order to realize the potential of regenerative medicine to end donor organ shortage. We are developing bioartificial platforms and systems not only to provide therapies but to serve as the foundational building blocks for the next generation of engineered functionalized tissues.
Ancilia Biosciences develops engineered bacterial therapies to treat diseases linked to the microbiome. It provides and develops novel bacterial therapies that target the viral components of the microbiome to address chronic diseases across immunology and oncology indications.
Repair Biotechnologies is a biotechnology company developing therapies based on the cholesterol-degrading platform. Its platform technology aims to reverse atherosclerosis, familial hypercholesterolemias, and other conditions in which excess or modified cholesterol drives pathology.
Octagon Therapeutics, a preclinical-stage biopharmaceutical company developing antibiotics for multi-drug resistant infections, Octagon has demonstrated effectiveness against the most critical pathogens as identified by the WHO. Octagon World Headquarters is based in the Pagliuca Life Lab directly adjacent to Harvard campus. This state-of-the-art facility has allowed Octagon to accelerate the development of our vital medicines with minimal overhead and equipment costs. Octagon’s management team includes highly skilled scientists, clinicians, and entrepreneurs with decades of research experience and deep expertise in drug development. The scientific team is growing and continues to add top research talent.
Circularis Biotechnologies develops a revolutionary technology to regulate gene expression and enable increased biotherapeutic production. It was founded in 2014 and is headquartered in Oakland, California.
Volumetric is an advanced biomaterials and biofabrication company that develops a 3D bioprinting platform intended to create materials with living cells with applications in biomaterials, cancer research, and human organ replacements.
Pragma Bio is a biotechnology company that mines microbiome drugs to treat cancer and autoimmune disease. The company employs its proprietary methods in genomic sequencing, artificial intelligence, and synthetic biology to discover biomarkers and therapeutics for challenging immunologic disorders. It offers a platform that aims to aggregate public and private data in order to generate a microbiome database and leverages analytical processes to discover connections between distinct and biologically related data in order to increase statistical power and drive discovery. In addition, the platform can be used to identify novel biomarkers to risk-stratify patients and predict clinical outcomes. It was co-founded by Peter McCaffrey, Kovi Bessoff, Ayin Vala, and Kareem Barghouti in Millbrae, California in 2018.
Contraline is developing the first long-lasting, non-hormonal, reversible contraceptive for men
Cloud First, Born Mobile. RockStep Solutions is revolutionizing drug discovery with a cloud informatics platform for managing data and operations. RockStep's flagship product, Climb, solves the problem of data chaos and operational inefficiencies which is causing a huge drop in ROI for drug research. Climb is transforming how work is conducted in tier-1 pharma, biotechs, CROS, and Academia
Excision BioTherapeutics is a private company focused on developing advanced gene-editing therapeutics to address the medical need for the treatment of life-threatening diseases caused by viral infections. They develop gene-editing medicines that eradicate or disrupt viral genes in human patients. Their mission is to advance gene-editing therapeutics for our indications into safe and efficacious medicines that will greatly improve the lives of infected individuals around the world.
EnClear Therapies is a Cambridge (USA) based life sciences company developing a device-based therapy to aid in the treatment of neurodegenerative disease and delivery and monitoring of cerebrospinal fluid (CSF). EnClear’s proprietary therapeutic platform focuses on removing toxic proteins from the CSF. The company’s first products will target improving the lives of patients with Amyotrophic Lateral Sclerosis (ALS) and Progressive Supranuclear Palsy (PSP).
Foresight is a technology-enabled psychiatry and therapy services company. We directly employ psychiatrists, therapists, psychiatric nurse practitioners to treat patients in our offices. Our team of software and biomedical engineers create technology alongside our providers to revolutionize the care we provide.
Ombre is a provider of a microbiome testing kit designed to incorporate personalized probiotics and microbiome testing. The company's microbiome testing kit offers subscription-based customized testing of the microbiome with a personalized probiotic created specifically for the individual to get actionable insights into the prevention of chronic diseases including obesity, cystic fibrosis, and Alzheimer's, enabling customers to treat root causes of gut problems.
Suggestic's platform enables health-related organizations to build and deliver personalized nutrition programs in a fraction of the time and cost through white label solutions or direct API integration. Powered by proprietary artificial intelligence, the Suggestic platform allows for the encoding of dietary programs as rulesets. It then enables data acquisition from users and members in the form of assessments, lab tests, and devices. Based on the rulesets of the program and the user data, the platform delivers personalized food recommendations in the form of meal plans, smart shopping lists, recipe and restaurant recommendations, food logging, and more.
Ombre is a provider of a microbiome testing kit designed to incorporate personalized probiotics and microbiome testing. The company's microbiome testing kit offers subscription-based customized testing of the microbiome with a personalized probiotic created specifically for the individual to get actionable insights into the prevention of chronic diseases including obesity, cystic fibrosis, and Alzheimer's, enabling customers to treat root causes of gut problems.
Intelligent Implants use wireless implantable electronics to stimulate, steer, and monitor bone growth. The company is a provider of electrotherapeutic devices that treat diseases and aids in the recovery of bone and other tissues. It uses data, engineering, and medicine to bring novel, active, and connected medical devices to healthcare. Its integrated devices facilitate treatment for the patient, as well as, decision making for the healthcare professional. Erik Zellmer, Rory Murphy, Martin Larsson, and John Zellmer co-founded the company in Cork, Ireland in 2014.
Leucadia Therapeutics is a privately-held pre-clinical stage company. They focus on Alzheimer's disease prevention and treatment. They develop a diagnostic algorithm for Alzheimer's disease risk based on big data.
OccamzRazor combines machine learning and first-in-class biological techniques to improve outcomes in drug discovery and development. Our analysis pipeline consists of two proprietary technologies, Panoramic AI and RazorBrain. Together, they are designed to extract data from unstructured text sources (publications, patient reported outcomes, etc.) and join them with structured data (genomics, proteomics, phenomics, etc.) to generate stronger drug discovery hypotheses and more valuable insights. Successful applications include data extraction and curation from biomedical text, novel target identification, and drug repurposing/repositioning.
EnClear Therapies is a Cambridge (USA) based life sciences company developing a device-based therapy to aid in the treatment of neurodegenerative disease and delivery and monitoring of cerebrospinal fluid (CSF). EnClear’s proprietary therapeutic platform focuses on removing toxic proteins from the CSF. The company’s first products will target improving the lives of patients with Amyotrophic Lateral Sclerosis (ALS) and Progressive Supranuclear Palsy (PSP).
We have reached an inflection point in history where chronic disease is killing more people than infectious disease. Seven out of every ten deaths and 86% of the health care costs in the United States are attributable to chronic disease. There are similar statistics in other countries. Our digital therapeutics product, Transform, delivers a digital therapeutics solution specifically targeted at diabetes prevention. Digital therapeutics combines the latest advances in software, hardware, cloud infrastructure and applied behavioral psychology to deliver a platform preventive health coaching in a convenient and flexible format. In 2018, we have launched our product in Latin America and the Middle East with a vision to be the global leader in culturally diverse, technology-driven behavioral change programs.
We have reached an inflection point in history where chronic disease is killing more people than infectious disease. Seven out of every ten deaths and 86% of the health care costs in the United States are attributable to chronic disease. There are similar statistics in other countries. Our digital therapeutics product, Transform, delivers a digital therapeutics solution specifically targeted at diabetes prevention. Digital therapeutics combines the latest advances in software, hardware, cloud infrastructure and applied behavioral psychology to deliver a platform preventive health coaching in a convenient and flexible format. In 2018, we have launched our product in Latin America and the Middle East with a vision to be the global leader in culturally diverse, technology-driven behavioral change programs.
Ligandal's mission is to create precision delivery platform to cure and treat disease. We are driving the discovery and delivery of a broad array of gene therapies, genetic materials, and gene-specific payloads with unprecedented precision at the cellular and sub-cellular level. Our ligand discovery engine allows for rapid design of diagnostically-responsive materials, capable of shuttling a variety of nucleic acid and protein payloads (including CRISPR and mRNA) to specific cell types. We are initially applying this technology to indications in hematology, immuno-oncology, and infectious disease.
Notable Labs is a personalized testing service for cancer patients that prioritizes combinations of FDA-approved treatments that can be immediately prescribed by a doctor without a clinical trial.
Echo is a provider of am automated microscope intended for biological research and pathologies. The company's product provides features like inverted images, cell counting, phase contrast, brightfield and fluorescence, enabling customers to have accurate images at a lower cost.
CrowdMed is revolutionizing healthcare by harnessing ‘the wisdom of crowds’ to help solve even the world’s most difficult medical cases quickly and accurately online. After 4 years of development and refinement, CrowdMed’s patented prediction market technology can uncover diagnoses to real-world medical cases that have stumped doctors for years. Instead of relying on individual physicians, CrowdMed harnesses the collective intelligence of thousands of Medical Detectives to produce astonishingly accurate and insightful diagnostic suggestions. Their goal is to be relied upon by millions of patients as a trusted source of medical answers. They combine the collective knowledge of human diagnosticians with the speed and convenience of the Internet.
Echo, we believe health is about people, not pills. That’s why we’ve created a new kind of pharmacy. One that comes to you, not the other way around. We start with being brilliant at fulfilling prescriptions because getting people taking the right medicine is the first step in staying well. But there’s more we can do. It’s not just patients we support, its partners. Together with other like-minded pharmacies, GPs and prescribing services we deliver even more positive experiences. Ultimately, we want to help patients understand and do more for themselves, so together they can make the right decisions with their GPs. And when it comes time to improve our health, we all know more Technology should make the future of health care more human. So ours comes packed with care.
Echo is a provider of am automated microscope intended for biological research and pathologies. The company's product provides features like inverted images, cell counting, phase contrast, brightfield and fluorescence, enabling customers to have accurate images at a lower cost.
Notable Labs is a personalized testing service for cancer patients that prioritizes combinations of FDA-approved treatments that can be immediately prescribed by a doctor without a clinical trial.